children on cART, 12.5% had clinical and/or immunological failure, while 28.8%, 44.2% and 48 26.9% had VL <1000, 1000-5000, and >5000 cp/ml, respectively. Clinical/immunological 49 failure poorly predicted virological failure. Dried blood spot (DBS) sampling is a promising tool for virological monitoring in LMIC (5-8).
60
Although the accuracy of VL testing with DBS may be affected by prolonged storage at high 61 temperatures and humidity (5) and by variability in nucleic acid extraction and amplification 62 using commercial and in-house methods (6, 9), most studies report high correlations between 63 plasma viral load and DBS when plasma viremia exceeds 5000 HIV-1 RNA cp/ml (6, 7, 9, 10). Median time from blood collection in Uganda to DBS shipment to the laboratory in Italy was 82 49(IQR 34-64) days. For each sample, RNA was extracted from two 50 μl of DBS (total volume 83 100 μl whole blood); total HIV-1 RNA (cell-associated plus plasma) levels were determined 84 using Amplicor HIV-1 Monitor test (Roche Diagnostic Systems) and the limit of detection was 85 170 HIV-1 RNA cp/ml whole blood, taking into account the spot volume (13).
86
Clinical and immunological failure were defined according to WHO 2010 criteria (Table 2) 87 (12). Differences in demographic and clinical characteristics by VL category were assessed using for VL>1000 or >5000 cp/ml was assessed using sensitivity, specificity, positive predictive value The baseline characteristics of 104 (51M,53F) children are listed in Table 1 . Median age of 95 children at specimen collection was 6.55(IQR 3.67-9.21) years. At birth, 2 children were exposed (Table 1) .
112
The sensitivity and specificity of clinical and/or immunological criteria in predicting virological 113 failure were very low at both 1000 and 5000 cp/ml whole blood thresholds (Table 2 ).
These findings indicate that a high proportion of children may have detectable viral load after at cART resistances makes it difficult to give an exhaustive explanation of the poor virological 123 outcome observed in our cohort.
124
As previously mentioned, HIV-1 RNA extracted from DBS comes from both plasma and cells.
125
Cell-associated residual viral replication may persist even in cART-treated patients with 126 undetectable plasma viremia (14) . In our cohort, VL from DBS may have been slightly 127 overestimated compared to plasma viremia, particularly in the <1000 and 1000-5000 cp/ml Table 1 . Univariate analysis of 104 cART experienced HIV-positive children with VL <1000, 3 1000-5000, and > 5000 cp/ml whole blood. * n=30 for VL <1000 cp/ml; n=74 for VL >=1000 cp/ml whole blood 15 ** n=76 for VL <5000 cp/ml; n=28 for VL >5000 cp/ml whole blood 
